Want to see SE:ISOFOL full AI Analyst Report?
Top Page
Isofol Medical AB
(ISOFOL)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr1.00
▲(38.89% Upside)
Action:Reiterated
Date:10/28/26
The score is held down primarily by weak fundamentals—minimal revenue, persistent losses, and material operating cash burn—partly offset by a low-debt balance sheet. Technical momentum is currently supportive (price above major moving averages and positive MACD), but valuation support is limited given the negative P/E and lack of dividend yield.
Positive Factors
Zero financial leverage
The absence of financial debt reduces refinancing exposure and interest-related pressure while preserving flexibility for research spending. This gives Isofol a stronger balance-sheet position than a similarly loss-making biotech carrying material leverage, although it does not remove its need for funding.
Negative Factors
No commercial revenue
The absence of product revenue means Isofol has not yet demonstrated a self-funding commercial model. Future value depends heavily on successful development, regulatory approval, and eventual market adoption of its candidate, leaving revenue visibility and operating scale weak over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero financial leverage
The absence of financial debt reduces refinancing exposure and interest-related pressure while preserving flexibility for research spending. This gives Isofol a stronger balance-sheet position than a similarly loss-making biotech carrying material leverage, although it does not remove its need for funding.
Read all positive factors
Isofol Medical AB (ISOFOL) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr367.28M
Dividend YieldN/A
Average Volume (3M)842.60K
Price to Earnings (P/E)―
Beta (1Y)-0.17
Revenue GrowthN/A
EPS Growth32.79%
CountrySE
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding320,491,640
10 Day Avg. Volume2,049,870
30 Day Avg. Volume842,595
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.19
Revenue Forecast (FY)N/A
Isofol Medical AB Business Overview & Revenue Model
Company Description
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is ...
How the Company Makes Money
As a clinical-stage biotechnology company, Isofol Medical AB has historically not generated recurring revenue from product sales (no approved commercial products). Its funding has therefore primarily come from external financing rather than operat...
Isofol Medical AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 721.00K | 12.80M | 22.41M |
| Gross Profit | 0.00 | 0.00 | -38.73M | -34.41M | -165.71M | -174.31M |
| EBITDA | -57.13M | -54.76M | -47.21M | -37.02M | -159.73M | -198.49M |
| Net Income | -56.63M | -54.17M | -43.49M | -37.07M | -159.79M | -200.25M |
Balance Sheet | ||||||
| Total Assets | 118.56M | 129.40M | 98.42M | 140.60M | 213.46M | 401.36M |
| Cash, Cash Equivalents and Short-Term Investments | 114.83M | 126.99M | 96.16M | 138.15M | 190.58M | 379.45M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 3.95M | 1.65M |
| Total Liabilities | 23.55M | 21.52M | 20.47M | 19.16M | 54.99M | 83.13M |
| Stockholders Equity | 95.01M | 107.87M | 77.94M | 121.43M | 158.48M | 318.23M |
Cash Flow | ||||||
| Free Cash Flow | -700.00K | -51.94M | -41.99M | -52.54M | -190.97M | -188.43M |
| Operating Cash Flow | -52.63M | -51.94M | -41.99M | -52.54M | -190.97M | -188.43M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 101.00K | 0.00 | 0.00 |
| Financing Cash Flow | 101.96M | 84.07M | 0.00 | 0.00 | 23.00K | 450.48M |
Isofol Medical AB Technical Analysis
Positive
0.72
Price Trends
0.81
Positive
0.79
Positive
0.74
Positive
Market Momentum
0.08
Negative
64.29
Neutral
78.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ISOFOL, the sentiment is Positive. The current price of 0.72 is below the 20-day moving average (MA) of 0.87, below the 50-day MA of 0.81, and below the 200-day MA of 0.74, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 64.29 is Neutral, neither overbought nor oversold. The STOCH value of 78.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ISOFOL.
Isofol Medical AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | kr416.43M | 2.17 | 63.09% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr367.28M | -5.73 | -54.41% | ― | ― | 32.79% | |
48 Neutral | kr189.86M | -8.04 | -56.09% | ― | ― | 14.10% | |
47 Neutral | kr716.05M | -2.13 | ― | ― | 87.23% | 35.27% | |
43 Neutral | kr1.36B | -2.74 | -99.58% | ― | -87.22% | -70.29% | |
43 Neutral | kr338.74M | -2.98 | -18.05% | ― | ― | 15.97% |
* Healthcare Sector Average
SE:ISOFOL
Isofol Medical AB
1.15
0.46
66.57%
SE:BINV
BioInvent International AB
20.70
-10.40
-33.44%
SE:ONCO
Oncopeptides AB
1.66
-3.59
-68.41%
SE:ELIC
Elicera Therapeutics AB
2.85
-3.08
-51.98%
SE:IMMU
Immunicum AB
5.34
-1.84
-25.63%
SE:CANTA
Cantargia AB
1.48
-2.02
-57.74%
Isofol Medical AB Corporate Events
Isofol schedules investor updates to showcase new data on cancer drug arfolitixorin
Oct 13, 2026
Isofol Medical will host an Investor Scientific Update in Stockholm on November 12, followed by a summary meeting in Gothenburg on November 13, to present new data and scientific insights on its lead drug candidate arfolitixorin. The events, feat...
Isofol to Highlight Cancer Drug Candidate at BioStock Investor Meetings
Sep 22, 2026
Isofol Medical AB, a Gothenburg-based clinical-stage biotech listed on Nasdaq Stockholm, is developing arfolitixorin, a proprietary next-generation folate treatment intended to enhance the effectiveness of established therapies for solid tumors. T...
Isofol Deepens Arfolitixorin Push as Cash Reserves Bolster Pre-Revenue Pipeline
Aug 25, 2026
Isofol Medical AB reported its interim results for January to June 2026, highlighting a continued strategic focus on clinical development rather than commercial revenues. The company remains pre-revenue, posting a first-half loss of kSEK -30,790, ...
Isofol expands arfolitixorin cancer trial to accelerate patient recruitment
Aug 24, 2026
Isofol Medical is expanding its phase Ib/II clinical study of arfolitixorin in colorectal cancer by adding new trial sites, including Essen University Hospital in Germany, to accelerate patient recruitment. The move follows regulatory approval of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.